{"component": "definition", "props": {"groups": [{"snippet": "means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).", "samples": [{"hash": "bshuXmUJQK8", "uri": "/contracts/bshuXmUJQK8#collaboration-compound", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 31.8446273804, "published": true}, {"hash": "2pRa9THPkRz", "uri": "/contracts/2pRa9THPkRz#collaboration-compound", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 28.950717926, "published": true}, {"hash": "jjBdizJCLoe", "uri": "/contracts/jjBdizJCLoe#collaboration-compound", "label": "License, Development and Commercialization Agreement", "score": 26.226556778, "published": true}], "size": 9, "snippet_links": [{"key": "hif-compound", "type": "definition", "offset": [49, 61]}, {"key": "to-this-agreement", "type": "clause", "offset": [97, 114]}, {"key": "section-36", "type": "clause", "offset": [127, 138]}, {"key": "the-foregoing", "type": "clause", "offset": [342, 355]}], "hash": "d206990562a98af788db652a7df81c4d", "id": 1}, {"snippet": "means, for a Collaboration Program, any compound (including any peptide, protein or nucleic acid), construct, composition or biological entity directed to the Collaboration Target identified for such Collaboration Program and arising from the conduct of such Collaboration Program which meets the criteria for further Development set forth in the applicable Research Plan, and any modification, variant or derivative thereof.", "samples": [{"hash": "eG6byZr8OmW", "uri": "/contracts/eG6byZr8OmW#collaboration-compound", "label": "License and Collaboration Agreement (Axovant Sciences Ltd.)", "score": 29.848733902, "published": true}, {"hash": "5vdlKKDRpA1", "uri": "/contracts/5vdlKKDRpA1#collaboration-compound", "label": "License and Collaboration Agreement (Benitec Biopharma LTD/ADR)", "score": 29.8268318176, "published": true}, {"hash": "3jJ6oQCD0aA", "uri": "https://investors.siogtx.com/static-files/2cc9fad4-a7c6-45c8-95c5-918f19bd7352", "label": "investors.siogtx.com", "score": 9.9938402176, "published": false}], "size": 8, "snippet_links": [{"key": "collaboration-program", "type": "definition", "offset": [13, 34]}, {"key": "nucleic-acid", "type": "definition", "offset": [84, 96]}, {"key": "directed-to", "type": "definition", "offset": [143, 154]}, {"key": "collaboration-target", "type": "definition", "offset": [159, 179]}, {"key": "conduct-of", "type": "clause", "offset": [243, 253]}, {"key": "the-criteria", "type": "clause", "offset": [293, 305]}, {"key": "further-development", "type": "definition", "offset": [310, 329]}, {"key": "the-applicable", "type": "clause", "offset": [343, 357]}, {"key": "research-plan", "type": "clause", "offset": [358, 371]}], "hash": "a6332ad4b680460a7809905831befb0d", "id": 2}, {"snippet": "means a Drug Candidate (and any Follow-On Compound with respect to such Drug Candidate) and/or a Future Program Compound (and any Follow-On Compound with respect to such Future Program Compound), as applicable.", "samples": [{"hash": "gi8NqCGkHFo", "uri": "/contracts/gi8NqCGkHFo#collaboration-compound", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.4544830322, "published": true}, {"hash": "9Uop5UAinMB", "uri": "/contracts/9Uop5UAinMB#collaboration-compound", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.421628952, "published": true}, {"hash": "6Dh96ZdWGv", "uri": "/contracts/6Dh96ZdWGv#collaboration-compound", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.3832988739, "published": true}], "size": 6, "snippet_links": [{"key": "drug-candidate", "type": "definition", "offset": [8, 22]}, {"key": "with-respect-to", "type": "clause", "offset": [51, 66]}, {"key": "future-program-compound", "type": "definition", "offset": [97, 120]}], "hash": "a8801fc1ef26baf0080fc31fd078fb55", "id": 3}, {"snippet": "means [ * ].", "samples": [{"hash": "j5iRQ4neSkQ", "uri": "/contracts/j5iRQ4neSkQ#collaboration-compound", "label": "Product Development and Commercialization Agreement (Exelixis, Inc.)", "score": 24.5947971344, "published": true}, {"hash": "havZonndlxv", "uri": "/contracts/havZonndlxv#collaboration-compound", "label": "Cancer Collaboration Agreement (Exelixis Inc)", "score": 21.0, "published": true}, {"hash": "lExE0uMiww0", "uri": "/contracts/lExE0uMiww0#collaboration-compound", "label": "Product Development and Commercialization Agreement (Exelixis Inc)", "score": 18.0, "published": true}], "size": 6, "snippet_links": [], "hash": "4eba7b8b8c85066765f243f194fbb7cd", "id": 4}, {"snippet": "means any of Lead Compound and/or Back-Up Compounds.", "samples": [{"hash": "5d7YyPKNNUt", "uri": "/contracts/5d7YyPKNNUt#collaboration-compound", "label": "License and Collaboration Agreement (Portola Pharmaceuticals Inc)", "score": 24.3456535339, "published": true}, {"hash": "hh56RRcZwNi", "uri": "/contracts/hh56RRcZwNi#collaboration-compound", "label": "License and Collaboration Agreement (Portola Pharmaceuticals Inc)", "score": 24.1950721741, "published": true}, {"hash": "f8ClBWXsfpb", "uri": "/contracts/f8ClBWXsfpb#collaboration-compound", "label": "License and Collaboration Agreement (Portola Pharmaceuticals Inc)", "score": 23.9705677032, "published": true}], "size": 6, "snippet_links": [{"key": "lead-compound", "type": "clause", "offset": [13, 26]}], "hash": "b468e42a99559c7ae15bb3b1ddb33f32", "id": 5}, {"snippet": "means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.5 and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).", "samples": [{"hash": "jjFXUvvjJ7T", "uri": "/contracts/jjFXUvvjJ7T#collaboration-compound", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 31.8446273804, "published": true}, {"hash": "cl63x8GGuIk", "uri": "/contracts/cl63x8GGuIk#collaboration-compound", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 31.5954818726, "published": true}, {"hash": "JoyD82EnjY", "uri": "/contracts/JoyD82EnjY#collaboration-compound", "label": "License, Development and Commercialization Agreement (Fibrogen Inc)", "score": 25.8076667786, "published": true}], "size": 5, "snippet_links": [{"key": "hif-compound", "type": "definition", "offset": [49, 61]}, {"key": "to-this-agreement", "type": "clause", "offset": [97, 114]}, {"key": "section-35", "type": "clause", "offset": [127, 138]}, {"key": "the-foregoing", "type": "clause", "offset": [341, 354]}], "hash": "5e0c9c26730ff3c1de3635ac7953d8e7", "id": 6}, {"snippet": "means a compound that (a) (i) is Controlled by a Party or its Affiliates on the Effective Date and is the subject of and researched or developed in the performance of the Research Activities, or (ii) is first Controlled by a Party after the Effective Date and was identified, developed, or generated by such Party in the performance of its Research Activities, and (b) satisfies the Inclusion Criteria.", "samples": [{"hash": "2sDyzVnaJQG", "uri": "/contracts/2sDyzVnaJQG#collaboration-compound", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.2902121834, "published": true}, {"hash": "ePTlG1r6D3N", "uri": "/contracts/ePTlG1r6D3N#collaboration-compound", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 37.0985626283, "published": true}, {"hash": "42jemUzzxtM", "uri": "/contracts/42jemUzzxtM#collaboration-compound", "label": "Collaboration and License Agreement (Odyssey Therapeutics, Inc.)", "score": 36.0444908142, "published": true}], "size": 5, "snippet_links": [{"key": "by-a-party", "type": "clause", "offset": [44, 54]}, {"key": "on-the-effective-date", "type": "clause", "offset": [73, 94]}, {"key": "subject-of", "type": "clause", "offset": [106, 116]}, {"key": "research-activities", "type": "definition", "offset": [171, 190]}, {"key": "after-the-effective-date", "type": "clause", "offset": [231, 255]}, {"key": "such-party", "type": "clause", "offset": [303, 313]}, {"key": "inclusion-criteria", "type": "definition", "offset": [383, 401]}], "hash": "45d236da8744f7e20bb8b8871fe22c8c", "id": 7}, {"snippet": "means any molecule that (a) has a molecular weight less than or equal to [ * ]; (b) has the ability to inhibit, activate or otherwise modulate the activity of a Mammalian Target (other than a Confirmed Target) or its encoded protein; and (c) such ability is identified by or on behalf of BMS or its Affiliate or sublicensee through the use to any material extent of a Mammalian Target (other than a Confirmed Target) or any information relating to a Mammalian Target (other than a Confirmed Target) developed by or on behalf of BMS or its Affiliate or sublicensee by material use of such Mammalian Target, the DNA sequence relating thereto, or any other Research Results disclosed to BMS hereunder that (i) directly relate to such Mammalian Target (other than a Confirmed Target) or the Target to which such Mammalian Target is related, and (ii) Remain Confidential at the time of such use, provided that the foregoing definition is subject to the limitations in Section 4.15.", "samples": [{"hash": "kRaZbPwYhOu", "uri": "/contracts/kRaZbPwYhOu#collaboration-compound", "label": "Research Collaboration and Technology Transfer Agreement (Exelixis Inc)", "score": 18.0, "published": true}, {"hash": "eATcaEe2gEZ", "uri": "/contracts/eATcaEe2gEZ#collaboration-compound", "label": "Research Collaboration and Technology Transfer Agreement (Exelixis Inc)", "score": 18.0, "published": true}, {"hash": "9cBr0xLNZ9V", "uri": "/contracts/9cBr0xLNZ9V#collaboration-compound", "label": "Research Collaboration and Technology Transfer Agreement (Exelixis Inc)", "score": 18.0, "published": true}], "size": 5, "snippet_links": [{"key": "equal-to", "type": "definition", "offset": [64, 72]}, {"key": "ability-to", "type": "definition", "offset": [92, 102]}, {"key": "the-activity", "type": "clause", "offset": [143, 155]}, {"key": "mammalian-target", "type": "definition", "offset": [161, 177]}, {"key": "confirmed-target", "type": "definition", "offset": [192, 208]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [269, 287]}, {"key": "material-extent", "type": "definition", "offset": [347, 362]}, {"key": "relating-to", "type": "definition", "offset": [436, 447]}, {"key": "material-use", "type": "definition", "offset": [567, 579]}, {"key": "other-research-results", "type": "definition", "offset": [648, 670]}, {"key": "relate-to", "type": "definition", "offset": [716, 725]}, {"key": "the-target", "type": "clause", "offset": [783, 793]}, {"key": "at-the-time", "type": "clause", "offset": [866, 877]}, {"key": "provided-that", "type": "definition", "offset": [891, 904]}, {"key": "the-foregoing", "type": "clause", "offset": [905, 918]}, {"key": "subject-to-the", "type": "definition", "offset": [933, 947]}], "hash": "2709061c3e810bca8299e1c9ceb34ec6", "id": 8}, {"snippet": "means: (a) Lead Compounds; (b) Development Candidates; or (c) any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, co-crystals, polymorphs, ester, or prodrug of the compounds set forth in clause (a) or (b) of this definition.", "samples": [{"hash": "4Hsfk5Ck2hu", "uri": "/contracts/4Hsfk5Ck2hu#collaboration-compound", "label": "Collaboration Agreement (Exelixis, Inc.)", "score": 25.5776863098, "published": true}, {"hash": "ezs3I69MKi2", "uri": "/contracts/ezs3I69MKi2#collaboration-compound", "label": "Collaboration Agreement (Exelixis Inc)", "score": 21.0, "published": true}, {"hash": "9R7ID7wI8os", "uri": "/contracts/9R7ID7wI8os#collaboration-compound", "label": "Collaboration Agreement (Exelixis Inc)", "score": 21.0, "published": true}], "size": 5, "snippet_links": [{"key": "lead-compounds", "type": "clause", "offset": [11, 25]}, {"key": "development-candidates", "type": "clause", "offset": [31, 53]}, {"key": "in-clause", "type": "clause", "offset": [201, 210]}], "hash": "e54ec7d395fdfa29e1c6784f26802163", "id": 9}, {"snippet": "means any ADC that is generated within the Collaboration Program, as well as the antibodies incorporated in the ADC.", "samples": [{"hash": "bLQKtSbDx2T", "uri": "/contracts/bLQKtSbDx2T#collaboration-compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 35.0095825195, "published": true}, {"hash": "cqepFxHXj6a", "uri": "/contracts/cqepFxHXj6a#collaboration-compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 34.9274482727, "published": true}, {"hash": "1VB3EexYc7d", "uri": "/contracts/1VB3EexYc7d#collaboration-compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 34.8288841248, "published": true}], "size": 5, "snippet_links": [{"key": "collaboration-program", "type": "definition", "offset": [43, 64]}], "hash": "7b68e7c36fa4d67022d36e81d60ab3dd", "id": 10}], "next_curs": "CmMSXWoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj8LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIfY29sbGFib3JhdGlvbi1jb21wb3VuZCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).", "size": 331, "title": "Collaboration Compound", "id": "collaboration-compound", "examples": ["CombiChem shall maintain aliquots of any <strong>Collaboration Compound</strong> that has been synthesized by CombiChem.", "Provided, however, that ADDEX must diligently develop such <strong>Collaboration Compounds</strong> as provided in 3.5 (however an additional year shall be added to the Time to Complete for commencing Phase I for the first <strong>Collaboration Compound</strong> pursued under this provision).", "ArriVent shall have the sole discretion to decide whether or not to advance any <strong>Collaboration Compound</strong> and which <strong>Collaboration Compound</strong>(s) will be advanced for further studies beyond the [***].", "The headings and captions in this Agreement are for convenience of reference only and in no way define or limit the scope or intend of this Agreement or any provision thereof.", "GlobeImmune and Celgene acknowledge that some Platform Patents may have claims that are not Platform Claims and do not recite a <strong>Collaboration Compound</strong>, a Celgene Development Compound or a Licensed Product but instead solely recite a compound that is outside the scope of this Agreement [*] (such claims, the \u201cNon-Collaboration Claims\u201d).", "Notwithstanding anything to the contrary in this Section 9.7.3, GlobeImmune\u2019s clinical trial sites shall have the right to publish summaries of results of Clinical Trials conducted by GlobeImmune at such site with respect to a Licensed Product incorporating a <strong>Collaboration Compound</strong> to the extent required under the applicable agreement(s) between GlobeImmune and such clinical trial sites.", "Upon exercise of a Celgene Program Option, all <strong>Collaboration Compounds</strong> (and any Follow-On Compounds with respect to such <strong>Collaboration Compound</strong>) within the Program for which Celgene exercises a Celgene Program Option shall be designated as Celgene Development Compound(s), unless and until this Agreement is terminated, whether in its entirety or with respect to such Celgene Development Compound(s) and such Program (alone or with other Programs).", "From time to time, Onyx may request Warner in writing to undertake specific research and development regarding a <strong>Collaboration Compound</strong> or to declare a <strong>Collaboration Compound</strong> to be a Collaboration Lead Compound.", "GlobeImmune shall be responsible for making or having made all of its requirements of any <strong>Collaboration Compound</strong>, including for example requirements for Clinical Trials, prior to exercise by Celgene of its Celgene Program Option with respect to such <strong>Collaboration Compound</strong>.", "For clarity, if the intellectual property rights are directed to a <strong>Collaboration Compound</strong> with respect to which Celgene has exercised its Celgene Program Option and a <strong>Collaboration Compound</strong> with respect to which Celgene has not exercised its option, Celgene shall nevertheless be entitled to negotiate the license."], "related": [["lead-compound", "Lead Compound", "Lead Compound"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["collaboration-target", "Collaboration Target", "Collaboration Target"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"], ["collaboration-product", "Collaboration Product", "Collaboration Product"]], "related_snippets": [], "updated": "2026-04-19T04:24:51+00:00"}, "json": true, "cursor": ""}}